Liqenza 32mg Oral Solution 150ml

About

Liqenza 32mg Oral Solution, containing Enzalutamide, is a potent androgen receptor inhibitor used in the treatment of various stages of prostate cancer. It works by binding to androgen receptors on prostate cancer cells, thereby inhibiting critical steps in androgen receptor signaling, including androgen receptor nuclear translocation, DNA binding, and transcription. This multi-step inhibition effectively prevents androgens (like testosterone) from stimulating the growth and proliferation of prostate cancer cells. Unlike traditional anti-androgens, Enzalutamide acts at multiple points of the androgen receptor signaling pathway, making it effective even in castration-resistant prostate cancer where androgen levels are low. The oral solution formulation provides an important alternative for patients who may have difficulty swallowing tablets, ensuring broader accessibility and adherence to treatment.

Uses

• Treatment of metastatic castration-resistant prostate cancer (mCRPC).
• Treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).
• Treatment of metastatic hormone-sensitive prostate cancer (mHSPC).
• Management of high-risk non-metastatic hormone-sensitive prostate cancer.

Directions For Use

Take Liqenza 32mg Oral Solution orally once daily, at the same time each day, with or without food. Measure the dose accurately using the provided dosing device.

Benefits

• Effectively inhibits androgen receptor signaling in prostate cancer.
• Improves overall survival and progression-free survival in mCRPC.
• Offers a non-chemotherapeutic oral treatment option.
• Can be used in both metastatic and non-metastatic settings.
• Oral solution form provides flexibility for administration.
• Helps delay disease progression and reduce prostate-specific antigen (PSA) levels.

Side Effects

• Asthenia/Fatigue
• Hot flashes
• Headache
• Hypertension
• Diarrhea
• Nausea
• Decreased appetite
• Peripheral edema
• Falls
• Seizures (rare)
• Fractures
• Musculoskeletal pain

Safety Measures

• Alcohol - Alcohol consumption should be limited as it may increase the risk of certain side effects, including seizures, or interact with the medication.
• Pregnancy - Liqenza is not indicated for women. It can cause fetal harm if administered to a pregnant woman. Men treated with Liqenza should use condoms during and for 3 months after treatment if their partner is pregnant or of childbearing potential.
• Breastfeeding - Liqenza is not indicated for women. It is unknown if it is excreted in human milk.
• Liver - Use with caution in patients with severe hepatic impairment; dose adjustments may be necessary. Monitor liver function tests regularly.
• Kidney - No dose adjustment is generally required for mild to moderate renal impairment. Use with caution in severe renal impairment.
• Lung - No specific lung-related safety concerns are commonly associated with Enzalutamide.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.